ScoreComparison
Why is Lineage Cell Therapeutics, Inc. ?
Unrated Stock - No Analysis Available
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Lineage Cell Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
49.68%
EBIT Growth (5y)
4.65%
EBIT to Interest (avg)
-28.88
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.59
Sales to Capital Employed (avg)
0.17
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
56.45%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
18.08
EV to EBIT
-17.66
EV to EBITDA
-18.25
EV to Capital Employed
-20.66
EV to Sales
33.20
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-80.84%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend11What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -20.4 MM
NET PROFIT(HY)
Higher at USD -6.11 MM
NET SALES(Q)
At USD 3.68 MM has Grown at 34.91%
RAW MATERIAL COST(Y)
Fallen by 0.24% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -171.8 %
OPERATING PROFIT(Q)
Highest at USD -3.61 MM
-3What is not working for the Company
ROCE(HY)
Lowest at -153.37%
DEBTORS TURNOVER RATIO(HY)
Lowest at 20.01 times
Here's what is working for Lineage Cell Therapeutics, Inc.
Operating Cash Flow
Highest at USD -20.4 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
At USD 3.68 MM has Grown at 34.91%
over average net sales of the previous four periods of USD 2.73 MMMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Profit
Higher at USD -6.11 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Operating Profit
Highest at USD -3.61 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Debt-Equity Ratio
Lowest at -171.8 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by 0.24% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Lineage Cell Therapeutics, Inc.
Debtors Turnover Ratio
Lowest at 20.01 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
